Uveal Melanoma Background Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. It arises from melanocytes in the uveal tract (iris, ciliary body, choroid) and has a devastating tendency to metastasize predominantly to the liver. Once metastatic, one-year overall mortality reaches 80-87%, and no effective systemic therapies exist.
What is RHPN1-AS1? RHPN1-AS1 is a 2,030-base-pair long non-coding RNA (lncRNA) located at chromosome 8q24.3 - a region frequently amplified in uveal melanoma and other solid tumors. Unlike protein-coding genes, lncRNAs do not produce proteins but instead regulate gene expression at multiple levels including chromatin modification, transcription, and post-transcriptional processing.
Main Findings RHPN1-AS1 was significantly overexpressed in UM cell lines and tissues compared to normal retinal pigment epithelium (RPE) cells. Silencing RHPN1-AS1 inhibited colony formation, migration, invasion, and tumor growth in mouse xenograft models, supporting its classification as an oncogenic lncRNA (oncoRNA).
Expression Profiling Microarray analysis comparing UM tissues with normal tissues identified RHPN1-AS1 as upregulated. This was confirmed by qRT-PCR in UM cell lines OCM1 and OM431, with RPE cells as the normal control. Fluorescence in situ hybridization (FISH) with cy3-labeled probes localized RHPN1-AS1 to the cytoplasm, further confirmed by nuclear/cytoplasmic fractionation.
Transient Knockdown via siRNA Three siRNAs were designed and tested against RHPN1-AS1. The most effective achieved approximately 70% knockdown in OM431 cells and 60% in OCM1 cells. Two siRNA sequences (si1 and si2) were selected for functional experiments.
Stable Knockdown via Lentiviral shRNA Two shRNA sequences were cloned into pGIPZ lentiviral vectors and used to generate stable knockdown cell lines (sh1 and sh2) in both OCM1 and OM431 backgrounds. Knockdown efficiency was confirmed by qRT-PCR, and stable lines were used for in vivo xenograft experiments.
Functional Assays Colony formation assays measured proliferative capacity over 8 days. Transwell migration assays (8 micrometer pore membranes) evaluated directional migration toward a serum gradient. Matrigel invasion assays assessed invasion through extracellular matrix. All assays were performed in triplicate.
Colony Formation RHPN1-AS1 knockdown significantly reduced the number of colonies formed by OCM1 and OM431 cells compared to control and mock groups (p less than 0.05). This indicates that RHPN1-AS1 supports UM cell proliferative capacity.
Migration and Invasion Transwell migration was inhibited by approximately 55% in OCM1 cells and 50% in OM431 cells following RHPN1-AS1 knockdown. Matrigel invasion assays showed a corresponding significant decrease in invasive potential (p less than 0.05 for both cell lines).
Xenograft Tumor Growth Subcutaneous injection of 1 million RHPN1-AS1-sh1 OCM1 cells into nude mice produced significantly smaller tumors compared to control OCM1 cells. By day 14 the difference in tumor volume was already significant, and at day 28 the average tumor weight in knockdown mice was significantly lower than controls (p less than 0.05).
Microarray After Knockdown Affymetrix microarray analysis comparing RHPN1-AS1-sh1 OCM1 cells with controls identified 136 genes with at least 2-fold change. Gene ontology (GO) analysis of these differentially expressed genes revealed enrichment in biological processes related to angiogenesis, cell adhesion, and extracellular matrix organization.
KEGG Pathway Analysis The most significantly changed signaling pathways included bladder cancer pathway signatures, nicotinate and nicotinamide metabolism, and critically the TGF-beta signaling pathway. TGF-beta is a major driver of epithelial-to-mesenchymal transition (EMT), which is central to cancer invasiveness and metastasis.
TGF-beta as a Mechanistic Clue The enrichment of TGF-beta pathway genes suggests that RHPN1-AS1 may promote UM progression at least partly through EMT induction. However, since RHPN1-AS1 did not affect the expression of its sense-strand neighbor RHPN1, the effects are likely trans-acting - regulating genes at distant loci rather than simply modulating the adjacent protein-coding gene.
Biomarker Potential Because RHPN1-AS1 is consistently overexpressed in UM cell lines relative to normal RPE cells, and given the absence of currently available molecular biomarkers for UM prognosis beyond chromosome 3 monosomy and BAP1 mutation status, RHPN1-AS1 merits evaluation as a tissue or liquid biopsy biomarker.
Therapeutic Relevance The 8q24.3 genomic locus is frequently gained in metastasizing UM tumors, and RHPN1-AS1 resides within this amplified region. Targeting oncogenic lncRNAs with antisense oligonucleotides (ASOs) or RNA interference is an active therapeutic strategy in cancer. The cytoplasmic localization of RHPN1-AS1 makes it more accessible to antisense approaches.
Connection to UM Biology Unlike cutaneous melanoma which frequently harbors BRAF mutations, UM is primarily driven by GNAQ and GNA11 mutations, along with BAP1 inactivation and chromosome 3 monosomy. Identifying downstream effectors like RHPN1-AS1 that are active in the 8q24.3 amplification context adds to the understanding of UM-specific oncogenic mechanisms.
Mechanistic Questions The precise molecular mechanism by which cytoplasmic RHPN1-AS1 promotes TGF-beta signaling and angiogenesis remains to be defined. Whether it acts as a competing endogenous RNA (ceRNA) sponging microRNAs, as a scaffold for protein complexes, or through other mechanisms requires further biochemical characterization.
Need for Patient Data This study used cell lines and xenograft models. Validation in UM patient tissue samples with survival data is needed to determine whether RHPN1-AS1 expression levels correlate with metastasis-free survival or overall survival.
Expanding to Primary UM The study focused on cell line models but did not demonstrate RHPN1-AS1 overexpression in primary UM biopsies with matched normal tissue. Such clinical tissue-based validation, combined with correlation to BAP1 mutation status and chromosome 3 monosomy, would determine whether RHPN1-AS1 constitutes an independent prognostic variable.